Skyrizi (risankizumab-rzaa) is a prescription injection used for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Skyrizi is typically given once every 8 to 12 ...

Skyrizi is available in multiple forms, including single-dose prefilled pens and single-dose prefilled syringes. The typical dosages of Skyrizi may vary depending on which condition is being treated.

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe "We know many people living with psoriasis are looking for ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Skyrizi is now available as a single-dose 150 mg ...

Turning to a next-gen psoriasis treatment to help drive future fortunes. One may boast the top-selling drug in the world for several years running and a market-leading position in a lucrative and ...

The approval was based on data from 2 pivotal phase 3 studies, which compared Skyrizi to placebo in adults with active PsA who had an inadequate response or were intolerant to biologic therapy and/or ...

NORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for ...